Beroni Group Co., Ltd. was successfully listed on the Australian National Stock Exchange IPO on May 12, 2017, and dual-listed on the Frankfurt Stock Exchange in Germany on January 19, 2018, becoming China's The first biotechnology company to be successfully listed in Australia and Germany.
Beroni Group Co., Ltd. is an international group enterprise integrating R&D, production and marketing. The group’s overseas R&D, production base and operation center are located in the beautiful Sydney, Australia’s largest coastal city. The Greater China headquarters is located in Hong Kong, and the Greater China R&D center and global marketing center are located in the beautiful coastal city of Tianjin.
The group's business mainly focuses on new drug development and clinical practice, research in the field of immune cell therapy, viruses and detection, Internet-based B2C e-commerce new retail platform for big health products and medical big data platform, etc.
As of December 2018, Beroni Group has obtained and is applying for 130 patents in China.
In addition, the joint research and development project between Beroni Group and Columbia University in the United States has obtained 4 international invention patents. The patents are applicable to China, Japan, Australia and the Middle East countries and have obtained patent protection.
Tianjin Beroni Biotechnology Co., Ltd., controlled by Beroni Group, won the titles of "Tianjin Patent Pilot Unit in 2018", "Tianjin Small and Medium-sized Technology Enterprises", and "National High-tech Enterprise". Obtained the certification of "China Market Credit AAA Credit Enterprise", and its air purifier products won the "Tianjin Key New Product" certificate.